Artelo Biosciences, Inc. (ARTL): R&D Expense
$5.42M
Year ended 2025-12-31
$3.82M
Trailing 12 months to 2026-06-30
+7.8%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.42M | -9.5% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $5.99M | +5.2% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $5.70M | +31.7% | 2025-03-03, From 2023-01-01 |
| 2022-12-31 | $4.32M | +14.3% | 2024-03-25, From 2022-01-01 |
| 2021-12-31 | $3.78M | n/a | 2023-03-31, From 2021-01-01 |
| No annual figure between 2020-08-31 and 2021-12-31. | |||
| 2020-08-31 | $1.92M | +75.7% | 2021-11-29, From 2019-09-01 |
| 2019-08-31 | $1.09M | -12.6% | 2020-11-04, From 2018-09-01 |
| 2018-08-31 | $1.25M | n/a | 2019-12-18, From 2017-09-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Artelo Biosciences, Inc. (ARTL) | 2025-12-31 | $5.42M | -9.5% |
| BullFrog AI Holdings, Inc. (BFRG) | 2025-12-31 | $1.80M | -19.0% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $3.64M | +19.5% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $1.04M | -84.4% |
| Lipella Pharmaceuticals Inc. (LIPO) | 2024-12-31 | $3.61M | +18.9% |
| Alaunos Therapeutics, Inc. (TCRT) | 2025-12-31 | $1.36M | +276.5% |
| Vaccinex, Inc. (VCNX) | 2024-12-31 | $12.54M | -24.3% |
| InMed Pharmaceuticals Inc. (INM) | 2026-06-30 | $3.03M | +7.3% |
| Hepion Pharmaceuticals, Inc. (HEPA) | 2025-12-31 | $445.5K | -96.2% |
Compare ARTL, BFRG, NTHI, ATXI side by side · Screen every company in Pharmaceutical Preparations ↗